Home › Funds › Octagon Capital Advisors LP › OCUL

Octagon Capital Advisors LP position in OCUL

OCULAR THERAPEUTIX INC · Health Care

Octagon Capital Advisors LP reported holding 599,900 shares of OCUL (OCULAR THERAPEUTIX INC) in its Q3 2026 13F filing — a position valued at US$4.6M, representing 0.61% of its reported portfolio and ranking #21 among its reported holdings. Octagon Capital Advisors LP has disclosed OCUL holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

Latest position (Q3 2026)599.90K sh
Reported value held$4.60M
Portfolio Weight0.61%
First reportedQ1 2024
Last changeReduce
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Octagon Capital Advisors LP's OCUL position evolved

Octagon Capital Advisors LP first disclosed a stake in OCUL in Q1 2024 at 2,425,000 shares (US$22.1M). The position peaked in Q4 2025 at 2,623,600 shares, worth US$31.9M. Across 11 filings, Octagon Capital Advisors LP increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 599,900 shares valued at US$4.6M — a reduction of -1,475,100 shares quarter over quarter.. Notable position changes include a 34% trim in Q2 2026 (shares fell 22% over the following quarter), a 71% trim in Q3 2026 (shares fell 22% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 2.42M $22.07M New
Q2 2024 2.42M $16.59M Hold
Q3 2024 2.42M $21.10M Hold
Q4 2024 2.42M $20.71M Hold
Q1 2025 2.42M $17.78M Hold
Q2 2025 2.42M $22.50M Hold
Q3 2025 2.62M $30.67M Add
Q4 2025 2.62M $31.85M Hold
Q1 2026 3.17M $26.82M Add
Q2 2026 2.08M $20.38M Reduce
Q3 2026 599.90K $4.60M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About OCUL and 13F data

OCUL (OCULAR THERAPEUTIX INC) is a Health Care company. 30 other funds we track also report a position in OCUL — the largest reported positions include Deep Track Capital, LP (US$168.3M), SUMMER ROAD LLC (US$95.6M), Avoro Capital Advisors LLC (US$95.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding OCUL

All OCUL fund holders →

FAQ

How long has Octagon Capital Advisors LP held OCUL?

Octagon Capital Advisors LP has disclosed OCUL holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

What is Octagon Capital Advisors LP's current position in OCUL?

As of Q3 2026, Octagon Capital Advisors LP holds 599.90K shares of OCUL (OCULAR THERAPEUTIX INC), valued at $4.60M, representing 0.61% of its reported portfolio and ranking #21.

Has Octagon Capital Advisors LP been buying or selling OCUL?

In the latest 13F filing (Q3 2026), Octagon Capital Advisors LP reduced its position in OCUL. The position peaked in Q4 2025 at 2.62M shares.

Which other funds hold OCUL?

Other major institutional holders of OCUL include Deep Track Capital, LP, SUMMER ROAD LLC, Avoro Capital Advisors LLC, among 30 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.